How long has Ozempic (semaglutide) been on the market?
GLP-1 receptor agonist medications, the class of medications that Ozempic® belongs to, have been on the market for close to 20 years. Byetta® (exenatide) was the first of this class to be FDA-approved in 2005. Ozempic is an injectable GLP-1 receptor agonist that was FDA-approved for the treatment of type 2 diabetes in December 2017. At that time, the available doses were 0.25mg, 0.5mg, and 1mg. In March 2022, the 2mg Ozempic dose was FDA-approved. Current GLP-1 receptor agonists that are FDA-approved for weight loss include Zepbound®, Wegovy®, and Saxenda®.
Form Health
Form Health is a virtual obesity medicine clinic founded in 2019 that provides science-based obesity care to help patients achieve their weight loss and health goals. Patients have the opportunity to achieve sustainable weight loss by working closely with an American Board of Obesity Medicine physician and a Registered Dietitian who is a Board Certified Specialist in Obesity and Weight Management. Each Care Team develops a personalized treatment plan based on a comprehensive review of their medical history that includes behavioral support, nutrition, physical activity, and medication, if appropriate.
